The ability of the gametes to escape detection by the immune system is vital to successful human reproduction. Furthermore, the observed capacity of the testis in some species to support tissue grafts without rejection (immunological privilege) indicates that spermatogenic cells are protected by local immunoregulatory mechanisms. One of these mechanisms involves targeting T cells for inactivation and destruction within the testicular environment. Although the fluids of the testis and ovary surrounding the developing gametes contain soluble factors that inhibit T cells, the identity of the molecule(s) responsible for this activity has been unknown. Using a specific T-cell proliferation assay to monitor bioactivity, these molecules were purified from bovine ovarian follicular fluid by methanol extraction and sequential reverse-phase HPLC (RP-HPLC). All purified active fractions coincided with the elution position on RP-HPLC of several small molecules ranging in size from 496 to 522 Da. The same molecules were localized to the immunosuppressive fractions of rat testicular interstitial fluid. The active molecules were identified, using capillary electrophoresis electrospray ionization mass spectroscopy, as lyso-glycerophosphocholines (lyso-GPCs), namely, 1-palmitoyl-sn-glycero-3-phosphocholine, 1-oleoyl-sn-glycero-3-phosphocholine, a 18:2a/lyso-GPC (putatively, 1-linoleoyl-sn-glycero-3-phosphocholine), and a 20:4a/lyso-GPC (putatively, 1-arachidonyl-snglycero-3-phosphocholine). Comparison of the bioactivity and mass spectroscopy profiles of two of the purified molecules with their synthetic standards confirmed the identification. These molecules inhibit T-cell proliferation in response to activation and induce apoptosis of these cells in a time-and dosedependent manner. The emergence of gonadal lyso-GPCs as potential regulators of critical immune events opens up new avenues of inquiry into the origins of autoimmune infertility and more generally into mechanisms of peripheral immunoregulation and the development of novel immunosuppressives.
INTRODUCTION
Ever since the concept of ''immunological privilege,'' defined as the capacity of certain tissues to avoid or delay rejection responses, was first enunciated [1] , immunological privilege of the gonads has been of particular interest. Privilege has been viewed as essential for providing protection from the host immune system for the developing gametes, which are profoundly autoantigenic [2, 3] . There is a considerable body of experimental evidence for successful graft survival within the testicular parenchyma, particularly in experimental rodent species [reviewed in 4, 5] . Comparable evidence for graft survival in the ovary is lacking, but autoimmune infertility due to reactions against ovarian and oocyte antigens is a well known albeit infrequent condition [2, 6] . The fact that such reactions affect only a small number of women suggests that specific immunoregulatory mechanisms may be at least as important in the ovary as they are in the testis. Significantly, both the testis and the ovary are similarly affected in autoimmune polyendocrine syndromes in humans and in experimental models of these diseases in animals, providing further indication for the existence of common immunoregulatory mechanisms in these organs [7] [8] [9] .
Both the testis and the ovary possess fully intact lymphatics and immune cells, including potentially autoreactive T cells, that circulate freely through these tissues [10, 11] . Given that other immune privileged tissues, which include the eye, central nervous system, and the feto-placental unit, exhibit significant restriction on immune cell access, privilege in the gonads may be seen as something of a paradox. In recent studies, however, it has become increasingly evident that immunological privilege is not necessarily due to restrictions on immune cell access. It is now clear that privilege must also involve tissuespecific, localized immunoregulatory mechanisms [12] [13] [14] .
A number of mechanisms underlying immune privilege have been proposed. These include specialized epithelial barriers, such as the trophoblast and blood-brain barrier, elevated expression of various regulatory cytokines and receptor ligands, deviation of antigen-presenting cell (dendritic cell and macrophage) function, specific regulatory lymphocyte subsets, and localized T-cell killing [5] . Recent transplant studies have suggested that the testis environment creates immunological deviation by inducing apoptosis of activated and memory T cells and by concomitant promotion of regulatory T-cell development through local dendritic cell activity [15, 16] . Active deletion of autoreactive T cells resulting from contact with Fas ligand expressed on the epithelial cells of the testicular seminiferous epithelium has been implicated in some studies [17] , but this hypothesis remains highly controversial [18] . On the other hand, suppression of T cells by soluble factors present in the fluids of the ovary and testis that surround the gametogenic compartments has been known for some considerable time [19] [20] [21] . The importance of these factors has been difficult to assess since they have never been identified.
Although established immunosuppressive cytokines such as transforming growth factor beta have been shown to play an immunoregulatory role in the testis, for example [22] , they cannot on their own account for the potent immunosuppressive (i.e., T-cell inhibitory) activity detectable in testicular fluid [21] . Consequently, the aims of this study were to isolate and identify the molecule or molecules responsible for the immunosuppressive activity of the gonadal fluids. It is established, for the first time, that this activity is due to several lyso-glycerophosphocholines (lyso-GPCs) with T-cell inhibiting properties.
MATERIALS AND METHODS

Glycerophosphocholine Lipid Standards
Lipid standards were obtained from Sigma Aldrich (St. Louis, MO) and Avanti Polar Lipids (Alabaster, AL). All lipid standards were stored under N 2 and oxidation status prior to use was checked using mass spectrometry, as described by Spickett and colleagues [23] . Lipid nomenclature used is according to that of Khaselev and Murphy [24] . All other reagents were obtained from Sigma Aldrich, unless otherwise indicated.
Collection of Gonadal Fluids
Bovine ovaries were collected from fresh abattoir material on ice. Bovine ovarian follicular fluid (bFF) was collected by aspiration after which it was stored frozen at À208C until required. Rat testicular interstitial fluid (rIF) was collected from normal adult male Sprague-Dawley rats via a 5-mm incision in the testis capsule at 48C, as previously described [21] , and stored at À208C until required. All procedures involving animals were performed in accordance with the National Health and Medical Research Council of Australia Guidelines on Ethics in Animal Experimentation and were approved by the Monash Medical Centre Animal Experimentation Ethics Committee.
Methanol Extraction, Reverse-Phase HPLC (RP-HPLC) Fractionation, and Lymphocyte Inhibition Screening Assay
Prior to processing, multiple aliquots of bFF were thawed and pooled. Pools of 25 ml were extracted in methanol (MeOH; BDH, Poole, UK) and fractionated on an initial C4 semipreparative RP-HPLC column (Grace Vydac, Hesperia, CA) in 0.1% trifluoroacetic acid (TFA) (Pierce, Rockford, IL)/30%-100% MeOH, as described previously [25] . Fractions were assessed for biological activity in an established lymphocyte proliferation inhibition in vitro bioassay, as previously described [21] . Briefly, isolated rat thymocytes stimulated with a polyclonal activator, phytohemagglutinin (PHA), were incubated with dilutions of unextracted fluid samples or purified fractions for 72 h, and proliferation was measured by incorporation of [ 3 H]-thymidine (PerkinElmer, Waltham, MA) over a subsequent 16-h incubation. Fractions showing biological activity were further fractionated on two analytical C8 columns (4.6 3 75 mm, Ultrapore, Altex, Berkley, CA), initially under neutral pH conditions in 10 mM ammonium acetate (BDH) pH 7.0, 0%-52.5% acetonitrile (ACN) (BDH) using a staggered gradient over 70 min at a flow rate of 1.0 ml/min, followed by acidic pH elution in 0.1% TFA pH 2.0, 0%-45% ACN over 75 min at a flow rate of 1.0ml/min. Both analytical runs utilized an operating temperature of 258C. The final purification step used a C18 microbore column (1.0 3 250 mm, 218 TP51, Grace Vydac) utilizing 0.1% TFA, pH 2.0, 32%-80% ACN over 70 min at an operating temperature of 508C and a flow rate of 50 ll/min.
Frozen aliquots of testicular interstitial fluid samples were thawed and pooled to a combined volume of 25 ml, which was then processed, as described for bFF, through the MeOH extraction procedure and fractionation on the C4 semipreparative RP-HPLC column using a 0.1% TFA/30%-100% MeOH linear gradient.
SDS-PAGE
Fractions obtained from the C4 RP-HPLC fractionation of bFF were run as previously described [25] on 18% SDS-PAGE gels in Tris-tricine buffer using a single electrode buffer under reducing conditions, and protein bands were identified by silver staining [26] .
Functional Validation Studies: T-Cell Proliferation Inhibition Assay
Mature T cells were obtained from spleens of adult male Sprague-Dawley rats by careful dissection and extrusion with sterile blunt forceps. The resulting cells were resuspended in 0.017 M Tris, 1.4 M NH 4 Cl, pH 7.4, and incubated at 378C for 7-10 min with gentle agitation to lyse erythrocytes. The cells were resuspended in Dulbecco modified Eagle medium (DMEM), and the proportion of viable cells was determined by trypan blue exclusion. Cells were plated (0.2 3 10 6 viable cells/well) in 100 ll of DMEM, 2.5% fetal calf serum (FCS) (Invitrogen, Carlsbad, CA) in a 96-well plate (Becton Dickinson, Franklin Lakes, NJ). As appropriate to each experiment, the T cells were activated by addition of 50 ll DMEM, 125 lM b-mercaptoethanol (b-ME), containing 1) a maximally stimulating dose of PHA (80 lg/ml, final assay concentration), 2) a suboptimal dose of PHA (10 lg/ml, final assay concentration) with or without recombinant rat interleukin 2 (IL2) (100 pg/ml; R and D Systems, Minneapolis, MN), or 3) 100 ng/ml phorbol myristate acetate (PMA) and 250 ng/ml ionomycin. Finally, 100 ll of DMEM containing dilutions of either partially purified or purified gonadal lymphocyte inhibitory fractions or lysoglycerophosphocholine (lyso-GPC) standards diluted in DMEM, 0.025% bovine serum albumin (BSA), were added. The cells were then incubated for a total of 48 h at 378C in 5% CO 2 /air. Proliferation was measured by addition of [ 3 H]-thymidine (0.5 lCi/well) added for the last 16 h of the incubation. Cells were harvested onto paper filters using a Packard Micromate 196-cell harvester (Packard Biosciences, Meriden, CT), and the incorporated radioactivity was measured in a Packard scintillation counter. Counting efficiency for the recovered radioactivity was routinely between 60% and 65%, and efficiency was not affected by the samples. Data are presented as counts per minute (cpm) without correction, or as % control (PHA-or PMA/ionomycin-stimulated) cpm.
Measurement of T-Cell Viability and Interleukin 2 Receptor Expression
Viable T cells were measured by flow cytometry, as previously described [27] . Briefly, cultured cells were resuspended in 100 ll of 10 mM HEPES (Merck, Darmstadt, Germany), 140 mM NaCl, 2.5 mM CaCl 2 , pH 7.4, and labeled with 16 lg/ml of fluorescein isothiocyanate (FITC)-conjugated recombinant annexin A5 (BD Biosciences Pharmingen, San Diego, CA), 5 lg/ml propidium iodide (PI), and either 0.1 lg/ml mouse anti-rat CD3 antigen, epsilon polypeptide (CD3E)-R-phycoerythrin (PE; BD Biosciences Pharmingen), or 0.1 lg/ml PE-conjugated mouse anti-rat IgG (negative controls) for 15 min at 48C. Cells were washed in 500 ll HEPES buffer and resuspended (1 3 10 6 cells in 500 ll) for analysis by gating on the T-cell (CD3E þ ) population using a MoFLO flow cytometer (DakoCytomation, Carpinteria, CA) and FACSummit V3.1 software (DakoCytomation). Viability was determined from the percentage of CD3E þ cells that were negative for both annexin A5 (as a marker of programmed cell death or apoptosis) and PI (as a marker of loss of cell viability) labeling.
T-cell activation was determined by measuring the expression of the alpha chain of the receptor for the autocrine T-cell growth factor IL2 (IL2RA; also called CD25) on the cell surface by flow cytometry. Cells were resuspended (13 10 6 cells/ml) in 100 ll staining buffer (0.1 M phosphate-buffered saline, 1% BSA, 0.01% sodium azide) and labeled with 1 lg/ml mouse anti-rat T-cell receptor alpha chain antibody (R73) or 1 lg/ml mouse IgG negative control (DakoCytomation). All incubations were for 15 min at 48C. Cells were washed (500 ll) and resuspended in 100 ll staining buffer containing 100 lg/ml PEconjugated horse anti-mouse secondary antibody (BD Biosciences Pharmingen). Cells were blocked with 100 ll of staining buffer containing 10% mouse serum, washed, and resuspended in 100 ll of staining buffer containing 1 lg/ml biotinylated mouse anti-rat IL2RA antibody (BD Biosciences Pharmingen), then washed and labeled with 0.1 lg/ml streptavidin-APC-Cy7 conjugate (BD Biosciences Pharmingen). Finally, cells were washed, resuspended in 500 ll staining buffer, and analyzed by flow cytometry as described previously.
Interleukin 2 Assay
Production of IL2 by rat primary spleen-derived T-cells was assayed using a Quantikine rat IL2 ELISA (R and D Systems), with recombinant rat IL2 as standard and a sensitivity of 15 pg/ml, intra-assay coefficient of variation (CV) of 3.2% and interassay CV of 9.9%.
Cell Proliferation Assays
The cell lines, Jurkat (a human T-cell lymphoma), MPC-11 (a mouse B-cell plasmacytoma), and U937 (a human monocyte lymphoma) were obtained from American Type Culture Collection (Manassas, VA) and maintained in 125-cm 2 Falcon flasks in DMEM containing 10% FCS at 378C, 5% CO 2 /air (pH 7.2-7.4). All cells lines were nonadherent and were passaged every 2-3 days to maintain growth. At the commencement of the proliferation assay, cell viability was determined by trypan blue staining, and cells were plated at an optimum concentration of 0. cpm, 104 700 6 19 900 cpm, and 167 400 6 9500 cpm (mean 6 SEM, n ¼ 3 consecutive cultures) for the Jurkat, MPC11, and U937 cell proliferation studies, respectively, and the data are presented as % control cpm.
Bovine Granulosa Cell Viability Assay
Bovine granulosa cells were isolated and cultured using a modification of the method of Gutierréz and colleagues [28] . Briefly, cells were released from small to medium-sized follicles by gentle scraping using a fine-gauge needle in DMEM:F12, filtered using a 100-lm mesh to remove cell clumps and oocytes, and collected by centrifugation (8000 3 g, 10 min). Red blood cells were lysed (378C, 5 min) using hypotonic ammonium chloride/sodium bicarbonate. The cells were resuspended in DMEM:F12 containing 1% FCS and 0.01% BSA and cultured for 48 h (398C, 5% CO 2 in air, pH 7.4) at a concentration of 1 3 10 5 viable cells/250 ll in a 96-well culture plate. The spent medium was replaced with 100 ll of fresh medium containing samples or standards in 1% FCS and 0.01% BSA (identical conditions to splenocyte assay), and the cells were cultured for a further 24 h. Control cultures were frozen and thawed twice to kill the cells and used as a measure of baseline activity. Cell viability was determined using a colorimetric assay (Promega CellTiter 96 AQ ueous One Solution Cell Proliferation Assay kit) that measures metabolic activity as an index of the number of viable cells [29] . Cell viability results were expressed as absorbance at 490 nm after 4 h.
Mass Spectrometry
Fractions that were biologically active in the rat lymphocyte inhibition assay were selected for analysis on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF-MS) and capillary electrophoresis electrospray ionization mass spectrometry (CE-ESI-MS) and subjected to multiple-stage fragmentation. MALDI-ToF-MS was performed with a Voyager DE-STR (Applied Biosystems, Foster City, CA) with delayed extraction in the reflectron mode to obtain accurate monoisotopic masses of the analytes. Samples and standards were spotted on 100-well stainless-steel plates together with a-cyano-hydroxycinnamic acid (Agilent Technologies, Palo Alto, CA) or 2,5-dihydroxybenzoic acid as matrix using the dried droplet method with a matrix/sample ratio of 1 to 1. CE-ESI-MS experiments were carried out on an Agilent 3D capillary electrophoresis system coupled to an MSD-SL ion trap mass spectrometer (Agilent) through a sheath liquid configuration. Capillary electrophoresis was performed with untreated fused-silica capillaries at þ30 kV, and 10 mM ammonium acetate in 20% ACN was used as the background electrolyte. The sheath liquid was 5 mM ammonium acetate in 50% MeOH. HPLC fractions were used without any further treatment, while the glycerophosphocholine lipid standards were dissolved in 50% MeOH for CE-MS analysis. Tandem mass spectrometry with helium as the collision gas under both the positive and the negative ion mode was conducted to elucidate the molecular structure of the analytes.
Statistical Analyses
Relative activity (potency), precision, slope, interassay CV, and recovery estimates for samples assayed at serial dilutions were obtained from log-linear transformed dose-response curves in the in vitro proliferation assays using standard parallel-line bioassay statistics. Comparisons between paired responses were determined by t-test. Comparisons between multiple means were determined by ANOVA following appropriate transformation to normalize the data and equalize variance or ANOVA on ranks in conjunction with Dunnett's test for multiple comparisons with a control group.
RESULTS
Initial Extraction and Fractionation of Lymphocyte Inhibitory Activity
Pooled samples of bFF and rIF inhibited lectin-stimulated polyclonal T-cell proliferation, as measured by [ 3 H]-thymidine incorporation in the in vitro lymphocyte inhibition screening assay, in a similar dose-dependent manner (Fig. 1, A and B) . As previously reported [21] , lower doses of rIF actually stimulated T-cell proliferation, but this stimulation was not observed for any bFF pools examined (data not shown). The inhibitory activity was effectively and reproducibly recovered by methanol extraction of the fluids and separation on a C4 RP-HPLC column. As extensive preliminary studies had indicated that the molecular properties of the inhibitory activity in both fluids displayed similar chromatographic properties (data not shown) and testicular IF is a very limited material for purification compared with ovarian FF, the purification protocols were developed and established using bFF as the primary source. During RP-HPLC, bioactivity from bFF eluted as two adjacent peaks: based on differences in apparent specific enrichment of activity relative to material detected on a silverstained SDS-PAGE gel, three regions of peak activity were identified and designated Ia (fractions 49-50), Ib (fractions 51-52), and II (fractions 55-56) (Fig. 1, C-E) . Region Ia on the leading edge of the first peak contained the highest specific enrichment of activity, while region II contained most activity but also considerable contamination with apolipoprotein A-II (APOA2). A novel apolipoprotein, apolipoprotein N (APON), recently shown to be associated with the bioactivity in methanol extracts [25] , overlapped the later bioactive fractions (fractions 57-59) of peak II. The elution position of these proteins, however, did not correspond with the inhibitory activity. Using the extraction and fractionation conditions established for isolation of activity from the bFF samples, similar activity profiles were obtained following extraction/ fractionation of rIF (refer to Fig. 5, A and B) . Pools of the bioactive RP-HPLC peak I and II fractions from extracted bFF or rIF were designated the ''lymphocyteinhibitory preparations'' (LIP) and used for subsequent functional characterization and/or purification studies. The bioactive preparations isolated from bFF in this manner displayed a 1.6-to 2.0-fold increase (P , 0.05) in the negative slope of the dose-response curves in the lymphocyte inhibition screening assay relative to the respective unfractionated gonadal fluid (Fig. 1A) , possibly due to the removal of interfering activities. Because of this change in slope following extraction, calculations of the recovery of bioactivity were estimated using the 50% inhibition of PHA-stimulated control (IC 50 ) value as a relative measure of activity, producing apparent recoveries of activity from bFF after methanol extraction of between 25% and 75% (in seven separate preparations). Precise estimates of the actual relative activity (potency) of the preparations were assessed using the T-cell proliferation inhibition assay; the combined data for the seven preparations, including the method of calculation of relative activity units (U), are presented in Table 1 .
In contrast to the results for bFF, recoveries of activity from the rIF pool were !100%, the high level of recovery being, in part, attributable to the removal of the lymphocyte-stimulating activity present in this fluid (Fig. 1B) . The relative potency of rIF-derived LIP, calculated from the IC 50 values, was 13.9 U/ ml, comparable to the activity of the bFF preparations (Table  1) .
Functional Characterization of Lymphocyte Inhibitory Preparations
In order to establish that the activity of LIP was not attributable to nonspecific blockade of [proliferation inhibition assay, inhibition was completely or partially abrogated when ovarian LIP was removed from the assay either prior to addition of the activating lectin, PHA (pretreatment) or after a brief period (6 h) following lectininduced activation (Fig. 2, A and B) . These data indicated that the inhibitory action of LIP on lymphocyte proliferation was, at least partially, reversible. When LIP was present throughout the assay period, complete inhibition of T-cell proliferation was generally observed at final assay doses of greater than 2.0 U/ ml.
Increasing doses of LIP also caused a decline in viable T cells in the culture, as measured by annexin A5/propidium iodide dual labeling (Fig. 2C) . However, even in the presence of LIP concentrations that completely inhibited T-cell proliferation, significant numbers of viable T cells remained present at the end of the culture. Representative flow cytometry data from the cell viability experiments are presented in Figure 2D . Within 24 h following PHA stimulation alone, a large percentage of the CD3E þ T cells had become annexin A5 labeled (apoptotic), as indicated by a shift to the right in the scatter plot. This may be attributed to T-cell damage during isolation as well as induced apoptosis by activation of a receptor-stimulated death pathway, presumably in preactivated T cells [30] . Apoptosis was considerably increased in the presence of a maximally inhibitory dose of LIP, with the majority of CD3E þ T cells expressing annexin A5 by 24 h of culture. By the end of the culture (72 h), many of the remaining cells in either treatment group were no longer viable, as indicated by a shift to the left of the scatter plot and a loss of annexin A5 binding, but viable CD3E þ T cells (lower left quadrant) continued to persist in the cultures. This indicated that some, apparently nonproliferating, T cells were resistant to the apoptotic effects of LIP in culture.
In the presence of increasing doses of LIP, the T cells also progressively lost the ability to produce the essential autocrine T-cell growth factor, IL2 (Fig. 3, A and B) . However, while the majority of surviving T cells continued to express the receptor for IL2 on their surface (64.3 6 6.1% of total R73
þ PI -cells were IL2RA þ [mean 6 SEM, n ¼ 3 experiments]) as a marker of their activation status, addition of exogenous IL2 did not significantly reverse the inhibitory activity of LIP (Fig. 3, C  and D) . The ability of LIP to inhibit proliferation of the Jurkat T-cell line also was examined. The IC 50 for inhibition of Jurkat cell proliferation by ovarian LIP was 2.8 6 0.4 U/ml, which was significantly greater than the IC 50 for inhibition of the PHA-activated primary T-cell cultures (P , 0.05). This indicates that the constitutively proliferating T-cell line was significantly less sensitive to the antiproliferative effects of LIP than polyclonally activated primary T cells. All together, these data indicated that LIP inhibits proliferation and IL2 production and responsiveness subsequent to T-cell activation and that the inhibition of T-cell responses to activation is followed by a progressive loss of lymphocyte viability. This loss of viability appears to be a consequence rather than the primary cause of the T-cell inhibition effects.
Purification and Mass Spectroscopic Analysis of Bioactive Species
Having established the functional parameters of LIP activity isolated from bFF, the bioactive regions Ia and Ib, which were comparatively free of apolipoproteins, were subsequently purified by serial C8 RP-HPLC and C18 RP-HPLC fractionation. Three distinct major peaks of activity eluted from the C18 microbore column: in order of increasing hydrophobicity, these peaks contained molecules of approximate masses [MþH] þ 520 Da, 544 Da, 1040 Da, 1064 Da (eluting at (Fig. 4) . However, an identical approach was used to identify the 522-, 520-, and 544-Da peaks. The mass spectroscopy data indicated that the larger m/z species were ''lipid dimers'' of the smaller molecules produced by limited self-assembly or aggregation during either the isolation or the MS analysis itself: homodimers of 496 Da (992 Da) and 522 Da (1044 Da) and a heterodimer of 520 Da and 544 Da (1064 Da). The elution positions of these molecules (mass determined by MALDI-ToF-MS) corresponded precisely to the peaks of bioactivity detected in all RP-HPLC profiles. Subsequently, the species with approximate masses of 496 and 522 Da also were identified as constituents in the APOA2 containing fractions (i.e., region II) of the initial C4 RP-HPLC separation (data not shown).
Following the isolation of the lymphocyte inhibiting molecules in bFF, species with identical masses were found to correspond with the bioactivity peak of methanol-extracted rIF fractionated on a C4 RP-HPLC column (Fig. 5) . These molecules eluted sequentially according to their relative apparent hydrophobicity, as was observed in the RP-HPLC elution profile of bFF, but did not resolve into two discrete peaks of activity (Fig. 5B) . Eluting prior to the inhibitory peak of activity was a complex peak of T-cell stimulating activity, the removal of which was consistent with the elevated recoveries of lymphocyte inhibitory activity in the extracted/ fractionated rIF preparation (see Fig. 1B ). Although this activity was not purified and identified, it most likely is due to the presence of interleukin 1, which is a major cytokine component of rIF collected from normal adult rats [21, 31] .
Molecular Identification of Bioactive Species by CE-ESI-MS
Following analysis by CE-ESI-MS and fragmentation of the ions (Fig. 6) corresponding to a molecular species of monoisotopic mass [MþH] þ : 496.33 Da (designated compound A), this bioactive molecule was identified as 16:0a/lyso-GPC, specifically 1-palmitoyl-sn-glycero-3-phosphocholine. The MALDI-ToF-MS profile for purified compound A (Fig.  4A ) was found to be identical to the equivalent profile of authentic synthetic 1-palmitoyl-sn-glycero-3-phosphocholine (Fig. 7) . Finally, this identification was confirmed more precisely by CE-ESI-MS fragmentation of authentic 1-palmitoyl-sn-glycero-3-phosphocholine, which gave a fragmentation pattern identical to that of compound A (Fig. 8) . Using the same approach, the molecular species of monoisotopic mass [MþH] þ : 522.35 Da (compound B) was identified as 18:1a/lyso-GPC (1-oleoyl-sn-glycero-3-phosphocholine) (data not shown). Authentic synthetic standards for the molecular species of monoisotopic mass [MþH] þ : 520.33 Da (compound C) and monoisotopic mass [MþH] þ : 544.32 Da 
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(compound D) were not available; however, these molecules were identified as an 18:2a/lyso-GPC (putatively 1-linoleoylsn-glycero-3-phosphocholine) and a 20:4a/lyso-GPC (putatively 1-arachidonyl-sn-glycero-3-phosphocholine), respectively (data not shown) [24] .
The lyso-GPCs are a class of lipids composed of a glycerophosphocholine backbone, with one free hydroxyl, at either the sn-1 or the sn-2 position, and having a long-chain fatty acid that is esterified at the sn-2 position if the free hydroxyl is at sn-1. When the hydroxyl substituent is at the sn-2 position, the sn-1 position can be either a long-chain ester, a long-chain vinyl ether, or a long-chain ether. Alternatively, phosphocholine lipids may be acetylated at the sn-2 position, as occurs in platelet-activating factor (PAF) [24] . All the glycerol-3-phosphocholine-containing molecules with T-cell inhibitory activity found in bFF or rIF were hydroxylated at the sn-2 position, with an ester-linked fatty acid at the sn-1 position.
Bioactivity Comparison of LIP and Lyso-GPC Standards
Final confirmation of the identity of the bioactive molecules in LIP derived from bFF or rIF was undertaken by comparing the bioactivity of purified LIP with the available synthetic standards. Both the compound A and B authentic synthetic standards were found to possess identical T-cell inhibitory biological activity with LIP extracted from bFF in the T-cell LYSO-GPCs AND GONADAL IMMUNOSUPPRESSION proliferation inhibition assay (Fig. 9, A-C) . These data indicated that 1 U/ml of LIP is equivalent in activity to approximately 25 lM of either compound A (1-palmitoyl-snglycero-3-phosphocholine) or compound B (1-oleoyl-sn-glycero-3-phosphocholine). LIP and the authentic standards also inhibited T-cell proliferation in response to direct activation by PMA/ionomycin in a similar manner over a similar dose range (Fig. 9, D-F) . A slight stimulation (30%-40%) of proliferation was observed at lower doses of both LIP and 1-oleoyl-snglycero-3-phosphocholine in some of the assays, but this was not consistently observed and did not achieve significance when all data were combined.
Cytotoxicity Assessment
In order to confirm that the effects of the gonadal lyso-GPCs were not associated with nonspecific cytotoxicity, bFF and purified ovarian LIP were added to bovine granulosa cell cultures that were subsequently assessed by a cell viability assay. In fact, bFF stimulated granulosa cell activity (i.e., proliferation) at doses up to 50 times greater than the effective IC 50 value of bFF in the lymphocyte proliferation assay (Fig.  10A) . Purified LIP had no effect on granulosa cell viability across the range of doses that inhibited lymphocyte proliferation, causing significant reduction of cell viability only at doses greater than five times the IC 50 in the lymphocyte assay: the IC 50 for LIP in the viability assay was 5.1 6 0.3 U/ml (mean 6 SEM, n ¼ 3 assays) (Fig. 10B) . For comparison, the IC 50 for the 1-palmitoyl-sn-glycero-3-phosphocholine standard in the granulosa cell viability assay was 128.3 6 6.1 lM (mean 6 SEM, n ¼ 3 assays), against an IC 50 of 25 lM in the lymphocyte proliferation assay. Comparison of the effects of a were either unaffected or significantly stimulated (Fig. 10C) . Together with the apoptosis and functional data presented here (Figs. 2, 3 ), these observations indicate that the T-cellsuppressing activity of the purified lyso-GPCs and standards involves specific and cell-selective induction of programmed 
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T-cell death across its active range of doses that cannot be attributed to nonspecific cell lysis or cytotoxicity.
DISCUSSION
Through a combination of classical high-resolution RP-HPLC, modern mass spectroscopy, and application of a robust T-cell proliferation bioassay, the T-cell inhibitory molecules of gonadal fluids have been identified as the specific lyso-GPCs, 1-palmitoyl-sn-glycero-3-phosphocholine, 1-oleoyl-sn-glycero-3-phosphocholine, a 18:2a/lyso-GPC (putatively, 1-linoleoyl-sn-glycero-3-phosphocholine), and a 20:4a/lyso-GPC (putatively, 1-arachidonyl-sn-glycero-3-phosphocholine). These molecules, whether isolated from gonadal fluid or synthetic, suppress T-cell proliferation, as measured by the ability to incorporate [ 3 H]-thymidine induced by either polyclonal activation, in either the presence or the absence of the T-cell growth factor IL2, or direct stimulation with PMA/ ionomycin in a partially reversible manner, inducing apoptosis of these cells in vitro. The data further indicate that this inhibition displays a degree of selectivity for proliferating T cells, as shown by the fact that T-cell proliferation could be completely inhibited by LIP, even though viable, activated (IL2RA þ ) CD3E þ T cells remained at the end of the culture. However, activated primary T-cell cultures were significantly more sensitive to inhibition than the constitutively activated and proliferating Jurkat T-cell line, which has been shown to be inhibited by lyso-GPCs in several previous studies [32] [33] [34] . Finally, the coextraction and adjacent elution profiles of the bioactive gonadal lyso-GPCs with the serum-derived apolipoprotein APOA2 and the gonad-derived apolipoprotein APON implicate these proteins as potential carriers and/or regulators of the bioactive molecules in gonadal fluids [25] . Physical association of the bioactive lyso-GPCs with these proteins may explain some apparently proteinaceous characteristics of unpurified immunosuppressive activity from gonadal fluids, described in earlier studies [19] [20] [21] . The crucial significance of the present study is the identification of the molecules responsible for the in vitro immunosuppressive activity of the gonadal fluids, and this will facilitate further studies on the regulation and physiological roles of these molecules in the ovary and testis.
Lyso-GPCs are typically generated by the specific action of phospholipase A 2 on membrane phosphatidylcholine-containing phospholipids, although they can also be produced by membrane oxidation and subsequent removal of the acetyl group at the sn-2 position by PAF acetylhydrolase [35] . They are found in the plasma membranes of cells and in most biological fluids, generally bound to albumin and lipoproteins in an inactive form [36] . Lysophospholipids, particularly those comprising saturated C16 and C18 fatty acids, have nonspecific membrane-disrupting effects at mid-lM concentrations [37] . For example, under the assay conditions used in the present study, 1-palmitoyl-sn-glycero-3-phosphocholine displayed evidence of cytotoxicity around 128 lM, consistent with previous reports using this lyso-GPC standard [38] . However, certain lyso-GPCs (in particular, 1-palmitoyl-snglycero-3-phosphocholine and 1-oleoyl-sn-glycero-3-phospho- choline) also have been found to exert specific biological actions at lower concentrations (typically between 5 and 50 lM). These lyso-GPCs have been shown to stimulate and/or inhibit the activation, proliferation, chemotaxis, or apoptosis of various cell types, including T cells, monocytes, endothelial cells, neural cells, and fibroblasts [32] [33] [34] [38] [39] [40] [41] [42] [43] [44] [45] [46] . The observation that lower doses of ovarian LIP and 1-oleoyl-snglycero-3-phosphocholine had minor stimulatory effects on Tcell activation in some cultures in the present study was consistent with the fact that these molecules can have stimulatory effects on T-cell activity under certain conditions as well [38] . Nonetheless, although lyso-GPCs have been reported to exert both stimulatory and inhibitory regulatory effects on T-cell proliferation events and to induce apoptosis of these cells, in previous studies [38, 47] , they have never been linked with immunoregulation in an immunologically privileged site before. Many details of the precise mechanisms whereby lysoGPCs exert their actions, including the suppression of proliferation and induction of apoptosis in T cells, have yet to be fully elucidated. However, an increase in cell permeability to calcium and an elevation of intracellular [Ca 2þ ]; increased reactive oxygen species production; signaling via mitogen-activated protein kinase 1 (MAPK1), MAPK3, and MAPK14; and direct or indirect effects on protein kinase C activity have all been implicated in studies using either T cells or other lyso-GPC responsive cell types [33, 34, 38, 39, 41, 42, 44, [46] [47] [48] . These observations are consistent with the observation in the present study that the gonadal-derived lyso-GPCs blocked PHA-induced, PHA/IL2-stimulated, and PMA/ionomycin-induced T-cell proliferation. Moreover, lysoGPCs have been postulated to act via specific G proteincoupled receptors on the surface of target cells, of which the orphan receptor proteins, G protein-coupled receptor 132 (GPR132) (also called the G2 arrest receptor or G2A) and G protein-coupled receptor 4 (GPR4) have been identified as candidates [41, 42, 44, 48] . Although the precise role of GPR132 and GPR4 in lyso-GPC signaling is currently in contention, deletion of GPR132 in mice results in systemic autoimmunity [49] , consistent with a critical role in endogenous immunosuppression and maintenance of tolerance. It should also be recognized that lyso-GPCs are able to enter the membrane themselves, so they may interact with membrane kinases, ion channels, and even G proteins directly, without the need for a specific receptor-ligand interaction.
Based on previous studies [33, 38, 41, 48] and the results of the present study, functional specificity for the lyso-GPCs appears to be related to the phosphatidylcholine at the sn-3 position and a small functional group at the sn-2 position (e.g., either hydroxyl or acetoyl), while the sn-1 position preferentially contains the C16 saturated or C18-C20 unsaturated fatty acids. While the acetylated PAF molecules, therefore, also possess immunosuppressive activity, the gonadal T-cell inhibitory lyso-GPCs lack the acetoyl group at the sn-2 position required for binding to the PAF receptor [35] , indicating a higher degree of functional specificity for these nonacetylated molecules. However, while PAF has been reported in both ovarian follicular fluid and the testis [50] , these molecules did not appear to make a significant contribution to the inhibitory activity isolated from either fluid.
Finally, it should be emphasized that lyso-GPCs are widely distributed and have been implicated in several immunoregulatory model systems [51, 52] . In fact, the absolute levels of total lyso-GPCs in human follicular fluid are similar to those found in serum [50] . Significantly, serum is considerably less effective as a suppressor of T-cell proliferation in vitro than either IF or bFF [21; Hedger, unpublished results], indicating that the molecular distribution of lyso-GPCs in gonadal fluids is different to that of serum or that there may be significant regulatory protein control. This would tend to indicate that the absolute levels of lyso-GPCs may be less important than the specific regulatory mechanisms that modulate their activity. Moreover, the presence of regulatory proteins, such as albumin and intragonadal apolipoproteins, presumably explains why follicular and testicular fluids do not display any evidence of cytotoxicity [21; Hedger, unpublished results], even though they contain putatively cytotoxic levels of lysophospholipids. The data also indicate that these local regulatory proteins block the cytotoxic effects of lyso-GPCs, without preventing their immunosuppressive activity. All together, these observations suggest that further studies on the composition and distribution of lyso-GPCs with immunosuppressive activity in gonadal fluids as well as the intragonadal proteins that regulate their activity may be an important aspect of their biology for future studies with respect to understanding immune privilege in these tissues.
In conclusion, the presence of these molecules in the fluids surrounding the developing gametes and the fact that the fluids have immunosuppressive activity that is attributable to their presence provides an entirely new avenue of exploration of the phenomenon of local immunosuppression and immune privilege associated with these tissues and has major implications for future studies of reproductive autoimmunity and infertility. For example, antibodies to PAF have been implicated in recurrent abortion, which is believed to have an autoimmune basis component in its etiology [53] , and it now appears that investigation of a role for antibodies against other lyso-GPCs in other infertility syndromes would be of considerable value. Moreover, the association of the lyso-GPCs with endogenous immunological privilege in the gonads points toward the exciting possibility that these compounds could be developed as alternatives to the problematic immunosuppressives currently used for prevention of transplant rejection.
